SOPHiA GENETICS (NASDAQ:SOPH) Announces Quarterly Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) announced its earnings results on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04), Zacks reports. The company had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 58.71%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q1 results — revenue of $21.7M (+22% YoY), a record 108,000 genomic analyses, and a 75.4% adjusted gross margin, which management says demonstrates the platform’s scalability.
• Network and retention — 537 institutional customers across 75 countries and ~2.5M profiles since inception; net dollar retention rose to 117% with multiple >$1M ACV expansion deals, supporting in-account upsell momentum.
• Biopharma traction — accelerating engagement with partners including AstraZeneca and J&J, plus efforts to build a global CDx and real-world evidence offering that management expects will be a material growth driver.
• Outlook and profitability path — the company reaffirmed 2026 revenue guidance of $92–$94M (20–22% growth) and adjusted EBITDA loss guidance of $29–$32M, and expects to approach adjusted-EBITDA breakeven by end-2026 and turn positive in H2 2027.
• Risks and headwinds — ongoing Guardant patent litigation (Q1 legal expense ~$1.4M, net ~$700k after interim recoveries), Swiss franc FX translation pressure raising dollar-reported costs, softness in Latin America, and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand.

SOPHiA GENETICS Stock Up 6.9%

Shares of SOPHiA GENETICS stock traded up $0.34 during trading on Thursday, reaching $5.36. The company’s stock had a trading volume of 84,015 shares, compared to its average volume of 164,634. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a market cap of $367.38 million, a price-to-earnings ratio of -10.31 and a beta of 1.01. SOPHiA GENETICS has a 1-year low of $2.59 and a 1-year high of $5.70. The company has a 50-day simple moving average of $4.83 and a two-hundred day simple moving average of $4.79.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 17,473 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $5.00, for a total value of $87,365.00. Following the completion of the sale, the chief executive officer owned 3,646,967 shares of the company’s stock, valued at $18,234,835. This trade represents a 0.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 193,859 shares of company stock valued at $943,777. 4.88% of the stock is owned by company insiders.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter worth $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth $54,000. XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth $55,000. Susquehanna International Group LLP purchased a new position in SOPHiA GENETICS in the 3rd quarter worth $88,000. Finally, Polen Capital Management LLC purchased a new position in SOPHiA GENETICS in the 4th quarter worth $102,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on SOPH. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Finally, Guggenheim raised their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.